Compare ADMA Biologics Inc (ADMA) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Corning Incorporated — how do they compare? ADMA Biologics Inc trades at $9.86 (market cap $2.22B), while Corning Incorporated trades at $167.27 (market cap $137.12B). The key difference: Corning Incorporated is far larger — about 61.8× ADMA Biologics Inc's market cap, and Corning Incorporated pays a 0.7% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | GLW | |
|---|---|---|
Market Cap | $2.22B | $137.12B |
Sector | Health | Technology |
52-Week High | $20.38 | $255.79 |
52-Week Low | $7.60 | $64.52 |
Enterprise Value | $2.29B | $144.00B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
GLW trades at $166.95, up 5.84% in the last session, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $0.78, beating expectations, driven by 17% YoY core sales growth from optical and AI data center demand. Valuation ratios are elevated, with a P/E of 73.36 and P/S of 8.23, while profitability improved with a net income margin of 11.2% in 2025.
The outlook is supported by AI infrastructure growth and analyst optimism, with a consensus price target of $193.33 implying 16% upside. Risks include premium valuation sensitivity and execution challenges in scaling solar and optical segments. Cash flow is projected to turn positive in 2026, but debt-to-asset ratio remains elevated at 27.67%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
